news
Pre-clinical study supports remdesivir as COVID-19 treatment
Scientists demonstrated that remdesivir can inhibit SARS-CoV-2 replication in human lung cells and improve lung function in mice with COVID-19.
List view / Grid view
Therapeutics
news
Study identifies eight novel coronavirus replication terminators
Scientists reveal eight new molecules, five of which are already US FDA-approved, that can block the polymerase reaction SARS-CoV-2 uses to replicate its genome.
news
Novel targeting peptide shows promise against COVID-19 cytokine storm
Experimental peptide combination TAT CARMIL1 reduced collagen degradation as a result of cytokine storm in ex vivo study.
news
Study reveals how SARS-CoV-2 rewires human proteins for replication
A team of researchers has analysed how SARS-CoV-2 hijacks the proteins in its host cells to aid replication and infect nearby cells.
news
Therapies targeting AhRs and IDO1 could combat COVID-19, paper says
Researchers have hypothesised that treatments targeting the downregulation of AhRs and IDO1 genes could reduce severity of COVID-19 infection.
news
Promising COVID-19 drug candidate identified by virtual screening
After virtually screening 640 existing drug compounds, researchers have revealed that PC786 potently targets several SARS-CoV-2 receptors, making it a candidate to fight COVID-19.
news
Over 718 drugs in pipeline as potential COVID-19 treatments, says report
New research has found that of the 718 pipeline drugs associated with COVID-19, 70 percent are currently in the discovery or pre-clinical stages.
news
PL8177 shows success as COVID-19 therapy in pre-clinical trials
The drug candidate PL8177 reduced inflammation, protected lung tissue and reduced lung fibrosis in pre-clinical models with symptoms of COVID-19.
news
N terminal domain of S protein revealed as antibody target for COVID-19
An antibody with high neutralising potency against SARS-CoV-2 that binds to the N terminal domain of the Spike protein has been identified by a team researching COVID-19 therapeutics.
article
3D bioprinting COVID-19 lung models for drug development
Keith Murphy, CEO of Viscient Biosciences, discusses the process of developing a 3D bioprinted tissue model and their potential in developing therapeutics for COVID-19 and other diseases.
news
Screening reveals nelfinavir and amodiaquine combat COVID-19 in cell cultures
Researchers who screened 136 broad-spectrum antivirals identified six with the most activity against COVID-19 and an optimum combination of two to fight the virus.
news
Decoy nanoparticles show success in cell cultures as COVID-19 therapy
Researchers have developed 'nanosponges' cloaked in lung cell membranes and macrophage membranes which they found could attract and neutralise COVID-19 in cell cultures.
news
New antibody cocktail developed as potential therapy for COVID-19
Researchers have proposed a cocktail of two antibodies which they say could provide an effective therapy for COVID-19 patients.
news
“Potent” antibodies provide protection from COVID-19 in cell cultures, finds study
Newly discovered antibodies found in the blood of recovered COVID-19 patients could provide robust protection against SARS-CoV-2, say researchers.
news
Naphthalene-based PLpro inhibitors show potential as COVID-19 therapeutics
A group of small molecules called naphthalene-based PLpro inhibitors have been shown to block the activity of a SARS-CoV-2 protein, demonstrating potential as COVID-19 therapeutics.